Rani Therapeutics Holdings, Inc. Logo

Rani Therapeutics Holdings, Inc.

Develops a capsule to convert injectable biologics into oral pills for chronic diseases.

RANI | US

Overview

Corporate Details

ISIN(s):
US7530181004
LEI:
Country:
United States of America
Address:
2051 RINGWOOD AVENUE, 95131 SAN JOSE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing orally administered biologics. The company has created the RaniPill® capsule, a proprietary and disruptive platform technology designed to convert injectable drugs, such as peptides, proteins, and antibodies, into oral pills. This technology aims to replace painful injections for patients with chronic diseases, potentially improving adherence and quality of life across a wide range of therapeutic areas. Rani's core business revolves around advancing its pipeline of oral biologic candidates through clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Rani Therapeutics Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Rani Therapeutics Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Rani Therapeutics Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.